ATE409495T1 - Polynukleotide-bindende komplexe die sterolen und saponine enthalten - Google Patents

Polynukleotide-bindende komplexe die sterolen und saponine enthalten

Info

Publication number
ATE409495T1
ATE409495T1 AT02759762T AT02759762T ATE409495T1 AT E409495 T1 ATE409495 T1 AT E409495T1 AT 02759762 T AT02759762 T AT 02759762T AT 02759762 T AT02759762 T AT 02759762T AT E409495 T1 ATE409495 T1 AT E409495T1
Authority
AT
Austria
Prior art keywords
complexes
saponins
methods
determinant
polynucleotide binding
Prior art date
Application number
AT02759762T
Other languages
German (de)
English (en)
Inventor
Nikolai Kirkby
Kristian Dalsgaard
Original Assignee
Nordic Vaccine Technology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Vaccine Technology As filed Critical Nordic Vaccine Technology As
Application granted granted Critical
Publication of ATE409495T1 publication Critical patent/ATE409495T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT02759762T 2001-04-04 2002-04-04 Polynukleotide-bindende komplexe die sterolen und saponine enthalten ATE409495T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100560 2001-04-04
US30860901P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
ATE409495T1 true ATE409495T1 (de) 2008-10-15

Family

ID=26069002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759762T ATE409495T1 (de) 2001-04-04 2002-04-04 Polynukleotide-bindende komplexe die sterolen und saponine enthalten

Country Status (7)

Country Link
EP (2) EP2011517A1 (enExample)
JP (2) JP2004528321A (enExample)
AT (1) ATE409495T1 (enExample)
DE (1) DE60229118D1 (enExample)
DK (1) DK1377320T3 (enExample)
NZ (1) NZ529347A (enExample)
WO (1) WO2002080981A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545605B8 (en) * 2002-10-02 2010-05-26 Nordic Vaccine A/S Composition for vaccination
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
PT2750683T (pt) 2011-10-03 2018-06-26 Mx Adjuvac Ab Nanopartículas, processo de preparação e seu uso como transportadores para moléculas hidrofóbicas anfipáticas no domínio da medicina, incluindo tratamento de cancro e compostos relacionados a alimentos
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
EP4234692A3 (en) 2017-07-11 2024-01-17 Freie Universität Berlin Novel uses of a saponin and method for its isolation
CN108498376B (zh) * 2018-04-02 2020-11-13 榛硕(武汉)智能科技有限公司 一种甲基硅油乳液及其制备方法
CN109295080B (zh) * 2018-09-19 2021-08-20 昆明理工大学 珠子参β-香树脂醇合成酶基因Pjβ-AS的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
GB2064320B (en) 1979-10-13 1983-10-12 Welsh Nat School Med Intra-ocular irrigation fluid
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4443432A (en) 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE450674B (sv) 1982-11-17 1987-07-13 Volvo Ab Kabelholje
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
CA1264668C (en) 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990004943A1 (en) 1988-11-09 1990-05-17 Unger Evan C Liposomal radiologic contrast agents
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
JPH04507244A (ja) 1989-07-27 1992-12-17 ユニバックス・バイオロジクス・インコーポレイテッド リピドa類似体/免疫原性担体コンジュゲートおよびそのワクチンとしての使用
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
EP0594640A4 (en) 1991-05-23 1998-06-03 Evan C Unger Liposoluble compounds for magnetic resonance imaging
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
AU1077795A (en) 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
US6077834A (en) * 1996-02-09 2000-06-20 Cheng; Pi-Wan Receptor ligand-facilitated delivery of biologically active molecules
BR9709993A (pt) 1996-06-25 1999-08-10 Stichting Inst Dierhouderij Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
JP3963506B2 (ja) * 1996-08-26 2007-08-22 俊彦 松尾 リポソーム点眼剤
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
WO1998048836A1 (fr) * 1997-04-30 1998-11-05 Merieux Oravax Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
DE19740092A1 (de) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge Liposomen und Verfahren zur Transfektion von Zellen
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
IL145117A0 (en) * 1999-03-02 2002-06-30 Liposome Co Inc Encapsulation of bioactive complexes in liposomes
EP1292330A1 (en) 2000-03-31 2003-03-19 Vaccine Chip Technology APS Immunostimulating properties of a fragment of tgf- beta

Also Published As

Publication number Publication date
NZ529347A (en) 2008-01-31
JP2004528321A (ja) 2004-09-16
EP1377320B1 (en) 2008-10-01
WO2002080981A2 (en) 2002-10-17
WO2002080981A3 (en) 2002-12-19
JP2010180249A (ja) 2010-08-19
EP1377320A2 (en) 2004-01-07
DK1377320T3 (da) 2009-02-09
DE60229118D1 (de) 2008-11-13
EP2011517A1 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
EP2322215A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
NO20053424L (no) Forbedrede farmasoytiske botulinumtoksin-preparater.
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
WO2005025508A3 (en) Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
HUE031034T2 (en) Methods for preventing and treating mucositis
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
ATE409495T1 (de) Polynukleotide-bindende komplexe die sterolen und saponine enthalten
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
Kaswan Natural resources as cancer-treating material
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
WO1999018998A3 (en) Delivery system
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
Chase et al. Curaderm, the long-awaited breakthrough for basal cell carcinoma
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
DE60129606D1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
WO2001080891A8 (en) Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
BG105924A (en) Composition for the treatment of psoriasis
JP2002325828A5 (enExample)
RU2000124052A (ru) Способ профилактики и лечения маститов у коров

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties